Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters

Frontiers in Immunology

Immunology

Eugenia Puentes¹  Esteban Rodríguez¹  Dolores Montenegro¹  Rafael Delgado²  Birgit Weynand³  Hendrik Jan Thibaut⁴  Winnie Kerstens⁴  Rana Abdelnabi⁵  Kai Dallmeier⁵  Lotte Coelmont⁵  Johan Neyts⁵  Mariano Esteban⁶  Guillermo Albericio⁶  David Astorgano⁶  Patricia Pérez⁷  Juan García-Arriaza⁷  Nuria Labiod⁸ 

[1] Biofabri, O Porriño, Pontevedra, Spain;Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain;Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain;Department of Microbiology, Hospital Universitario 12 de Octubre, Madrid, Spain;Department of Medicine, Medical School, Universidad Complutense de Madrid, Madrid, Spain;Department of Imaging and Pathology, Translational Cell and Tissue Research, Division of Translational Cell and Tissue Research, KU Leuven, Leuven, Belgium;Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Translational Platform Virology and Chemotherapy, KU Leuven, Leuven, Belgium;Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium;Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain;Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain;Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain;Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain;

关键词: COVID-19;    SARS-CoV-2;    variants of concern;    MVA-S(3P) vaccine candidate;    prefusion-stabilized spike;    hamsters;    immunogenicity;    efficacy;   

DOI  :  10.3389/fimmu.2023.1163159

 received in 2023-02-10, accepted in 2023-09-27,  发布年份 2023

来源: Frontiers

【 摘 要 】

The development of novel optimized vaccines against coronavirus disease 2019 (COVID-19) that are capable of controlling the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and the appearance of different variants of concern (VoC) is needed to fully prevent the transmission of the virus. In the present study, we describe the enhanced immunogenicity and efficacy elicited in hamsters by a modified vaccinia virus Ankara (MVA) vector expressing a full-length prefusion-stabilized SARS-CoV-2 spike (S) protein [termed MVA–S(3P)]. Hamsters vaccinated with one or two doses of MVA-S(3P) developed high titers of S-binding IgG antibodies and neutralizing antibodies against the ancestral Wuhan SARS-CoV-2 virus and VoC beta, gamma, and delta, as well as against omicron, although with a somewhat lower neutralization activity. After SARS-CoV-2 challenge, vaccinated hamsters did not lose body weight as compared to matched placebo (MVA-WT) controls. Consistently, vaccinated hamsters exhibited significantly reduced viral RNA in the lungs and nasal washes, and no infectious virus was detected in the lungs in comparison to controls. Furthermore, almost no lung histopathology was detected in MVA-S(3P)-vaccinated hamsters, which also showed significantly reduced levels of proinflammatory cytokines in the lungs compared to unvaccinated hamsters. These results reinforce the use of MVA-S(3P) as a vaccine candidate against COVID-19 in clinical trials.

【 授权许可】

Unknown   
Copyright © 2023 Abdelnabi, Pérez, Astorgano, Albericio, Kerstens, Thibaut, Coelmont, Weynand, Labiod, Delgado, Montenegro, Puentes, Rodríguez, Neyts, Dallmeier, Esteban and García-Arriaza